Mabapi le kankere / kalafo / liteko tsa bongaka / testicular-cancer
Liteko tsa meriana ea kalafo ea mofets'e oa testicular
Liteko 1-4 ho tse 4
Nivolumab le Ipilimumab ho phekola bakuli ba nang le lihlahala tse sa tloaelehang
Karolo ea II ea liteko tsa liteko tsa nivolumab le ipilimumab ho phekola bakuli ba nang le lihlahala tse sa tloaelehang. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka nivolumab le ipilimumab, e ka thusa sesole sa 'mele ho hlasela mofetše, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Teko ena e ngolisa barupeluoa bakeng sa lihlopha tse latelang tse ipapisitseng le maemo: 1. Lihlahala tsa epithelial tsa masapo a nko, libe, nasopharynx: A) Squamous cell carcinoma e nang le mefuta e meng ea masapo, li-sinus, le nasopharynx le trachea (ntle le laryngeal, nasopharyngeal cancer [NPC] , le squamous cell carcinoma ea hlooho le molala [SCCHN]) B) Adenocarcinoma le mefuta e meng ea masapo, lisosa le nasopharynx (e koetsoe ho fihlela 07/27/2018) 2. Lihlahala tsa epithelial tsa litšoelesa tse kholo tsa salivary (li koetsoe ho fihlela ho 03) / 20/2018) 3. Mofuta oa tšoelesa ea "salivary" ea hlooho le molala, molomo, 'metso, mala, trachea le matšoafo, sefuba le sebaka se seng (se koetsoeng ho fihlela se le seng) 4. Kankere e sa khetholloeng ea pampiri ea meno (GI) 5. Adenocarcinoma e nang le mefuta e meng ea mala a manyane (e koetsoe ho fihlela e le teng) 05/10/2018) 6. Squamous cell carcinoma e nang le mefuta e fapaneng ea pampitšana ea GI (mala a manyane, mala, rectum, manyeme) (e koetsoe ho fihlela 10/17/2018) 7. Fibromixoma le grade ea mucinous adenocarcinoma (pseudomixoma peritonei) ea sehlomathiso le ovary (e koetsoe ho fihlela ka la 03/20/2018) 8. Lihlahala tse sa tloaelehang tsa pancreatic tse kenyeletsang acinar cell carcinoma, mucinous cystadenocarcinoma kapa serous cystadenocarcinoma. Pancreatic adenocarcinoma ha e tšoanelehe 9. Intrahepatic cholangiocarcinoma (e koetsoe ho fihlela ka la 03/20/2018) 10. Extrahepatic cholangiocarcinoma le li-tumor tsa bile (tse koetsoeng ho fihlela ka la 03/20/2018) 11. Sarcomatoid carcinoma ea matšoafo 12. Bronchoalveolar carcinoma lung. Boemo bona hona joale bo boetse bo bitsoa adenocarcinoma in situ, adenocarcinoma e hlaselang hanyane, adenocarcinoma e nang le lepidic, kapa adinocarcinoma e hlaselang 13. A lihlahala tse sa sebetseng tsa ovary: A) Lefu la sele la germ la ovary B) hlahala e tsoakiloeng ea Mullerian le adenosarcoma (e koetsoe) ho bokella 03/30/2018) 14. Lefu la trophoblastic: A) Choriocarcinoma (e koetsoe ho ea ho e tlatsetsang) 15. Transitional cell carcinoma ntle le ea renal, pelvis, ureter, kapa senya (e koetsoe ho ea bokellaneng) 16. Tumelo ea sele ea 'mele lihlahala le lihlahala tsa kokoana-hloko ea extragonadal: A) Seminoma le kankere ea testicular ea thobalano B) Lefu le sa sebetseng C) Teratoma e nang le phetoho e mpe (e koetsoeng ho fihlela e eketseha) 17.
Sebaka: libaka tse 895
Tlhokomelo e sebetsang, Bleomycin, Carboplatin, Etoposide, kapa Cisplatin ho phekola bakuli ba bana le batho ba baholo ba nang le likokoana-hloko tsa lisele tsa likokoana-hloko. . Ho beha leihlo ka mafolofolo ho ka thusa lingaka ho lekola bafo ba nang le lihlahala tsa likokoana-hloko tse kotsing e tlase kamora hore hlahala ea bona e tlosoe. Lithethefatsi tse sebelisitsoeng chemotherapy, joalo ka bleomycin, carboplatin, etoposide, le cisplatin, li sebetsa ka mekhoa e fapaneng ho emisa kholo ea lisele tsa hlahala, ekaba ka ho bolaea lisele, ka ho li emisa ho arohana, kapa ka ho li emisa ho hasana. Sebaka: libaka tse 460
Inotuzumab Ozogamicin le Post-Induction Chemotherapy ho phekola bakuli ba nang le kotsi e phahameng ea B-ALL, Mixed Phenotype Acute Leukemia, le B-LLy
Karolo ena ea liteko tsa karolo ea III e hlahloba hore na inotuzumab ozogamicin e kentsoe chemotherapy ea kamora ho kenella bakeng sa bakuli ba nang le High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) e ntlafatsa litholoana. Teko ena e boetse e ithuta sephetho sa bakuli ba nang le phenotype e hlobaetsang leukemia (MPAL), le B-lymphoblastic lymphoma (B-LLy) ha ba alafshoa ka Phekolo e TSOHLE ntle le inotuzumab ozogamicin. Inotuzumab ozogamicin ke anti-monoclonal antibody, e bitsoang inotuzumab, e hokahaneng le mofuta oa chemotherapy o bitsoang calicheamicin. Inotuzumab e khomarela lisele tsa mofets'e ka tsela e shebiloeng mme e fana ka calicheamicin ho li bolaea. Lithethefatsi tse ling tse sebelisoang kalafong ea chemotherapy, joalo ka cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, 'me pegaspargase e sebetsa ka litsela tse fapaneng ho emisa kholo ea lisele tsa mofetše, ekaba ka ho bolaea lisele, ka ho li emisa ho arohana, kapa ka ho li emisa ho hasana. Teko ena e tla ithuta le liphetho tsa bakuli ba nang le phenotype e hlobaetsang leukemia (MPAL) le ho hasoa B lymphoblastic lymphoma (B-LLy) ha ba alafshoa ka chemotherapy e kotsing. Morero oa kakaretso oa thuto ena ke ho utloisisa hore na ho eketsa inotuzumab ozogamicin ho chemotherapy ea tlhokomelo e boloka kapa ho ntlafatsa sephetho ho High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). Karolo ea pele ea boithuto e kenyelletsa mekhahlelo e 'meli ea pele ea kalafo: Ho kenella le ho kopanya. Karolo ena e tla bokella tlhaiso-leseling ka kankere ea mali, hammoho le litlamorao tsa kalafo ea mantlha, molemong oa ho arola bakuli lihlopheng tsa kalafo kamora ho kopanya. Karolong ea bobeli ea phuputso ena, bakuli ba tla fumana methati e setseng ea chemotherapy (tokiso ea nakoana I, ho lieha ho matlafatsoa, tokiso ea nakoana II, tlhokomelo), le bakuli ba bang ba hlophiselitsoeng ho fumana inotuzumab. Morero o mong oa phuputso ena o kenyelletsa ho etsa lipatlisiso tsa hore na ho phekola banna le basali ka nako e ts'oanang ea chemotherapy ho boloka sephetho bakeng sa banna ba kileng ba alafshoa selemo se seng ha ho bapisoa le banana, le ho lekola mekhoa e metle ea ho thusa bakuli ho latela molomo. mekhoa ea chemotherapy. Kamora nako, phuputso ena e tla ba ea pele ea ho lekola sephetho sa lithuto ka lefu la B-cell Lymphoblastic Leukemia (B LLy) kapa Mixed Phenotype Acute Leukemia (MPAL) ha le alafshoa ka B-ALL chemotherapy. bakuli ba tla fumana methati e setseng ea chemotherapy (tokiso ea nakoana I, ho lieha ho matlafatsoa, tokiso ea nakoana II, tlhokomelo), le bakuli ba bang ba hlophiselitsoeng ho fumana inotuzumab. Morero o mong oa phuputso ena o kenyelletsa ho etsa lipatlisiso tsa hore na ho phekola banna le basali ka nako e ts'oanang ea chemotherapy ho boloka sephetho bakeng sa banna ba kileng ba alafshoa selemo se seng ha ho bapisoa le banana, le ho lekola mekhoa e metle ea ho thusa bakuli ho latela molomo. mekhoa ea chemotherapy. Kamora nako, phuputso ena e tla ba ea pele ea ho lekola sephetho sa lithuto ka lefu la B-cell Lymphoblastic Leukemia (B LLy) kapa Mixed Phenotype Acute Leukemia (MPAL) ha le alafshoa ka B-ALL chemotherapy. bakuli ba tla fumana methati e setseng ea chemotherapy (tokiso ea nakoana I, ho lieha ho matlafatsoa, tokiso ea nakoana II, tlhokomelo), le bakuli ba bang ba hlophiselitsoeng ho fumana inotuzumab. Morero o mong oa phuputso ena o kenyelletsa ho etsa lipatlisiso tsa hore na ho phekola banna le basali ka nako e ts'oanang ea chemotherapy ho boloka sephetho bakeng sa banna ba kileng ba alafshoa selemo se seng ha ho bapisoa le banana, le ho lekola mekhoa e metle ea ho thusa bakuli ho latela molomo. mekhoa ea chemotherapy. Kamora nako, phuputso ena e tla ba ea pele ea ho lekola sephetho sa lithuto ka lefu la B-cell Lymphoblastic Leukemia (B LLy) kapa Mixed Phenotype Acute Leukemia (MPAL) ha le alafshoa ka B-ALL chemotherapy. Morero o mong oa phuputso ena o kenyelletsa ho etsa lipatlisiso tsa hore na ho phekola banna le basali ka nako e ts'oanang ea chemotherapy ho boloka sephetho bakeng sa banna ba kileng ba alafshoa selemo se seng ha ho bapisoa le banana, le ho lekola mekhoa e metle ea ho thusa bakuli ho latela molomo. mekhoa ea chemotherapy. Kamora nako, phuputso ena e tla ba ea pele ea ho lekola sephetho sa lithuto ka lefu la B-cell Lymphoblastic Leukemia (B LLy) kapa Mixed Phenotype Acute Leukemia (MPAL) ha le alafshoa ka B-ALL chemotherapy. Morero o mong oa phuputso ena o kenyelletsa ho etsa lipatlisiso tsa hore na ho phekola banna le basali ka nako e ts'oanang ea chemotherapy ho boloka sephetho bakeng sa banna ba kileng ba alafshoa selemo se seng ha ho bapisoa le banana, le ho lekola mekhoa e metle ea ho thusa bakuli ho latela molomo. mekhoa ea chemotherapy. Kamora nako, phuputso ena e tla ba ea pele ea ho lekola sephetho sa lithuto ka lefu la B-cell Lymphoblastic Leukemia (B LLy) kapa Mixed Phenotype Acute Leukemia (MPAL) ha le alafshoa ka B-ALL chemotherapy.
Sebaka: libaka tse 189
Chemotherapy e potlakileng kapa e tloaelehileng ea BEP ho phekola bakuli ba nang le likokoana-hloko tse mahareng kapa tse mpe.
This randomized phase III trial studies how well an accelerated schedule of bleomycin sulfate, etoposide phosphate, and cisplatin (BEP) chemotherapy works compared to the standard schedule of BEP chemotherapy in treating patients with intermediate or poor-risk germ cell tumors that have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as bleomycin sulfate, etoposide phosphate, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BEP chemotherapy on a faster, or “accelerated” schedule may work better with fewer side effects in treating patients with intermediate or poor-risk metastatic germ cell tumors compared to the standard schedule.
Location: 139 locations
Nolofatsa maikutlo hore a ikhatholle